J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.
Drugs
Health
Pharma
Drugs
Health
Pharma
GSK drug gets Britain’s nod to treat UTI patients 12 years and above
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.
Drugs
Health
Pharma
Biogen’s drug to treat postnatal depression gets UK regulator’s nod
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Health
Opinion
Research
The Tomoe test: Self-taught schools need open skies, human touch, peers
A modern home can love a child deeply, but without open skies and rich human interaction, love alone is not enough. Homeschooling can.
Health
Research
Research reveals first child after age 30 increases breast cancer risk by over 40%
HQ Team August 18, 2025: Research finds that women who have their first child after age 30 face a 40% to 45% higher.
Drugs
Health
Implant TAR-200 eliminates bladder cancer in over 80% of high-risk cases in trials
HQ Team August 18, 2025: An implant called TAR-200 has shown remarkable results in treating high-risk bladder cancer. According to a recent Phase.
Drugs
Pharma
Research
Immunotherapy drug shows promising results against metastatic cancers
HQ Team August 16, 2025: Phase I clinical trial of the CD40 agonist antibody drug 2141-V11, developed by Rockefeller University’s Jeffrey V. Ravetch.
Health
Medical
Medical journal refuses to retract vaccine study as demanded by US health secretary
HQ Team August 14, 2025: The Annals of Internal Medicine has refused to retract a recent study that refuted any connection between aluminum.
Uncategorized
ADHD medication linked to lower risk of suicidal behaviour, study finds
August 14, 2025: A new study conducted by researchers at the University of Southampton in the UK and the Karolinska Institute in Sweden.
Uncategorized
Bayer and Kumquat Biosciences ink $1.3 billion deal to develop cancer inhibitor
HQ Team August 13, 2025: Bayer and Kumquat Biosciences, a clinical-stage biotech, announced an exclusive global license and collaboration agreement worth $1.3 billion.